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Abstract
Recent discoveries shed light on the importance of
prostaglandin (PG) production in the development of
skin cancer. Work by Fischer et al. demonstrates that
skin tumor promotion caused by ultraviolet B radiation
can be decreased by up to 89% by blocking cyclo-
oxygenase-2 (COX-2 ) with the drug Celecoxib. A
similar study showed that Celecoxib can decrease new
tumor formation by 44% in mice that already have
tumors. These studies demonstrate the importance of
COX-2 and PGs in the development of squamous cell
carcinoma. We have explored growth signaling in a
model of skin tumor progression. Because changes in
PG production have been implicated in skin carcino-
genesis, we examined this pathway. We found that
malignant cell lines secrete more prostaglandin E2
(PGE2) than the parental cells. We observed increased
expression of COX-1 and -2. We also found that these
cells express the PGE2 receptors EP1 and EP4. When
the cells are grown in the presence of indomethacin, the
growth rate of the malignant cells is decreased. This
effect can be reversed by addition of PGE2 or an EP1
agonist to the medium. Thus, we have shown that skin
tumor cells depend in part on PGE2 signaling through
the EP1 prostanoid receptor for their in vitro growth.
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Introduction
Prostaglandins (PGs) mediate numerous physiological
responses including inflammatory and immune responses,
bone development, wound healing, hemostasis, glomerular
filtration, production of the extracellular matrix, and cell
proliferation [1–5]. Prostaglandin E2 (PGE2) alone has
been shown to be active in many of these processes
including induction of matrix metalloproteinases, bone
resorption, induction of oncogenes, and induction of
cyclooxygenase-2 (COX-2) [6–16]. PG production
involves activation of phospholipase A2 (PLA2) releasing
arachidonic acid (AA) from the cell membrane. AA then
serves as a substrate for either COX-1 or -2, or PGH
synthase. These enzymes display the same enzymatic
activity, but are the products of two different genes
[17,18]. COX-2 has been shown to be inducible by
various factors including ultraviolet B and 12-O - tetrade-
canoylphorbol -13-acetate (TPA) [19–22]. There are also
reports that COX-1, although generally constitutively
expressed, can be induced by agents such as 4-(methyl-
nitrosamino)-1- (3-pyridyl ) -1-butanone derived from nic-
otine and PGE2 [23,24]. The activity of the COX enzymes
produces PGH2. This is then further metabolized to other
PGs or thromboxanes. The production of PGE2 from
PGH2 is dependent on PGE synthase, also referred to as
PGH–PGE isomerase [25–27]. Thus, PG production
requires several enzymatic steps, some of which can be
regulated.
PG production in the skin is inducible by numerous
stimuli including UV radiation [28,29] and treatment with
the phorbol ester TPA [30–32]. Both of these can act as
tumor-promoting agents [19,33]. There is evidence to
suggest that at least some of the tumor-promoting effects
of these agents are mediated by stimulation of PGE2
production [19,28,30–32,34–36]. Work by Fischer et al.
[37] has shown that blocking COX-2 activity with a
selective inhibitor (Celecoxib) significantly decreased the
tumor yield produced by ultraviolet B irradiation of hairless
mice. This decrease was dose dependent with respect to
Celecoxib. They also showed that the nonselective COX
inhibitor, indomethacin, could produce a similar effect [37].
Mu¨ller -Decker et al. [38] also provided evidence that
induction of COX-2 is an essential step for mouse skin
two-stage carcinogenesis. They showed increased PGE2
production due to COX-2 induction in skin treated with
TPA. In this study, they found that repeated applications of
TPA resulted in stationary hyperplasia and a loss of the PG
response. However, in papillomas and carcinomas, con-
stitutive overexpression of COX-2 and increased PG
production persisted. This result was confirmed in kerati-
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nocyte cell lines corresponding to different stages of tumor
development. It is of interest that inhibition of COX-2 can
inhibit growth of a human cutaneous squamous cell
carcinoma cell line [39].
Other work indicates that tumor promoters like TPA
stimulate PGE2 production in primary cultures of mouse
epidermal cells [40]. Also of interest is the fact that
smokeless tobacco extracts can increase PGE2 production
in human gingival keratinocytes [41]. PGE2 production has
also been linked to several events important to cancer
formation and spread. Addition of PGE2 to growth medium
can increase the growth rate of human keratinocytes [42].
Expression of the oncogenes JunB and p65 can be induced
by PGE2 [43]. PGE2 production can also increase migration
and adherence in a head-and-neck squamous cell carci-
noma cell line [44].
PGE2 has been shown to signal through several
pharmacologically distinct receptors [45]. These are G-
protein–coupled receptors classified according to their
binding affinity for various agonists or antagonists, and are
called EP1, EP2, EP3, and EP4 prostanoid receptors. The
EP2 and EP4 prostanoid receptors both signal through
increased adenylyl cyclase activity, whereas the EP3
prostanoid receptor decreases the activity of this enzyme
[45]. The EP1 prostanoid receptor signals through increased
activity of PLC- [45]. This results in release of diacylgly-
cerol (DAG) and inositol triphosphate ( IP3) [46]. These
receptors are most likely responsible for the downstream
effects of PGE2 and thus could be important in several
disease states including skin cancer.
Dysregulation of PGE2 production is a common finding in
skin cancer [28,30,31,47]. In the present study, we
assessed potential dysregulation of PGE2 production in a
murine model of skin tumor progression developed in our
laboratory [48]. We observed increased expression of the
COX enzymes in the malignant SCC progressed cell lines
compared to the precursor benign papilloma–producing cell
line. Total PGE2 measurements showed that these enzymes
are active. We further observed that the cells express the
EP1 and EP4 prostanoid receptors. We then established that
signaling through the EP1 prostanoid receptor is partially
responsible for the in vitro growth of these cells.
Materials and Methods
Cell Culture
The murine keratinocyte cell line 308 was progressed with
LD90 doses of  rays (750 cGy) from a
60Co source. The
resulting cells were injected subcutaneously into athymic
nude mice, and a cell line started from the resulting tumors.
This is cell line 6R90 [48]. Cell line 6RI (6RInvasive) was
established at a later date from an unusually invasive 6R90
tumor. The cells were maintained in minimal essential
medium supplemented with 7.5% fetal calf serum, 2.5% calf
serum, and 100 U/ml penicillin /streptomycin (Life Technol-
ogies, Rockville, MD) at 378C in a humidified atmosphere
containing 7% CO2.
Isolation of Cytoplasmic Protein and Western Blot Analysis
Cytoplasmic protein was isolated from subconfluent
cultures using published protocols [48]. Briefly, the cells
were rinsed with PBS and buffer A (10 mM HEPES pH 7.9,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT), and then lysed by
adding 0.1% NP-40 in buffer A to the cells on the plate and
scraping the plate. The lysate was then transferred to a 1.5-
ml plastic tube. Nuclei were pelleted by centrifugation and
the proteins extracted in buffer C (20 mM HEPES pH 7.9,
25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM DTT, 0.5 mM PMSF). The supernatant was diluted
1:6 with buffer D (20 mM HEPES pH 7.9, 20% glycerol, 1.5
mM MgCl2, 100 mM KCl, 0.2 mM EDTA, 0.5 mM DTT, 0.5
mM PMSF) and the extracts were stored at 808C until
used. The protein concentrations of the extracts were
determined with Bio-Rad reagent (Bio-Rad Laboratories,
Hercules, CA). Forty micrograms of cytoplasmic extract was
resolved on a 10% SDS–polyacrylamide gel and analyzed
by Western blot using antibodies against COX-1 (1:250
dilution, cat# sc-1752; Santa Cruz Biotechnology, Santa
Cruz, CA) or COX-2 (1:3000 dilution, cat# PG26; Oxford
Biochemicals, Oxford, MI) or PGE synthase (1:250 dilution,
cat# 160140; Caymen Chemical, Ann Arbor, MI).
Growth Curves
A total of 1104 cells were plated in six-well plates and
grown for 2 days as described above. Triplicate wells were
treated with ethanol or 10 M indomethacin or 10 M
indomethacin and PGE2 or agonist. The amount of PGE2 or
selective agonist added was based on the amount of PGE2
present in the medium of normally grown cells as shown in
Figure 3, and indexed to reflect cell number in the growth
curve experiment. Every 12 hours, medium was replaced,
and PGE2 or agonist was added based on the amount that
would be present at the end of the following 12 hours. The
maximum dose was 1.67 nM. These cells were trypsinized
every 12 hours in triplicate and the cells were counted on a
Coulter Counter. Mean cell numbers were plotted against
time to generate growth curves for all three cell lines. The
selective EP1 and EP3 agonist 17-phenyl trinor PGE2 was
purchased from Caymen Chemical (Ann Arbor, MI).
PGE2 Measurement
Total cellular PGE2 was measured by enzyme immuno-
sorbent assay (EIA). TheEIA apparatus was purchased from
Amersham (Piscataway, NJ). Briefly, cells were lysed in
medium and a sample was taken. The sample was incubated
with antibody and a PGE2 conjugate. The plate was then
washed and the substrate was added. The plate was
incubated for 1 hour. The reaction was then halted by addition
of 1 M sulfuric acid, and the results were read at 450 nm.
In Vivo Tumor Growth
5106 Cells from the cell lines were injected subcuta-
neously at four sites into athymic nude mice (BALB/c, nu/
nu, Harlan Sprague-Dawley, Indianapolis, IN). Tumors were
harvested and sections were stained with hematoxylin and
eosin (H&E).
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EP Receptor Staining
Antibodies to human EP1 and EP4 receptors were
generated in chickens using recombinant fusion proteins
containing glutathione-S - transferase and a portion of the
carboxy terminus of the EP4 receptor or the third intracellular
loop of the EP1 receptor [49]. Cells were grown on
coverslips to 60% confluence. Medium was aspirated, and
coverslips were washed in PBS. Cells were fixed with 4%
paraformaldehyde. Coverslips were washed in PBS, and
incubated in 30 mM SSC. Coverslips were incubated in 300
mM glycine, then in permeabilization buffer (0.1% Triton X-
100 in 30 mM SSC). Coverslips were placed in primary
antibody diluted 1:250 in antibody dilution buffer, and
incubated overnight at 48C. Coverslips were washed, and
then placed in fluorescein 5- isothiocyanate (FITC)-con-
jugated rabbit anti–chicken secondary antibody (cat# F-
8888; Sigma Chemical Co., St. Louis, MO) diluted 1:1000.
Samples were then washed. Two microliters of 40,60 -
diamidino-2-phenylindole (DAPI) was added to the final
wash. The coverslips were mounted on glass slides for
viewing, and the stained cells were then imaged.
RNA Preparation
Cells were cultured from a 10-cm dish and centrifuged at
3000 rpm for 5 minutes at 48C, then suspended in 400 l of
ice-cold lysis buffer and placed on ice. Lysis buffer contained
140 mM NaCl, 1.5 mM MgCl2, 10 mM Tris–HCl (pH 8.6),
0.5% NP-40, and ribonuclease (RNase) inhibitor (10 mM
vanadyl ribonucleotide complexes). The cell mixture was
slowly loaded onto 400 l of sucrose lysis buffer and
centrifuged at 3000 rpm for 10 minutes at 48C. Sucrose
lysis buffer was lysis buffer with the addition of 24% sucrose
to the solution. The supernatant was mixed with 400 l of 0.2
M Tris–HCl (pH 7.5), 25 mM EDTA, 0.3 M NaCl, 2% SDS,
and 200 g/ml of proteinase K, incubated at 378C for 40
minutes, extracted with phenol, and precipitated with sodium
acetate and ethanol.
Reverse Transcription–Polymerase Chain Reaction
(RT-PCR)
Cytoplasmic RNA (20 g) was treated with DNase for 15
minutes at room temperature, then 25 mMEDTA was added,
and the reaction was inactivated at 658C for 10 minutes. Four
microliters of oligo(dT) was added, and the reaction was
heated for 10 minutes at 708C. First strand synthesis was
carried out by adding 10 l of the RNA (10 g) mix to 9 l of
the RT mix. The RT mix contained 5 l of first strand buffer
(250 mM Tris–HCl pH 8.3, 375 mM KCl, 15 mMMgCl2), 1 l
dNTP (10 mM), 2 l DTT (0.1 M), and 2 l DEPC–H20 per
10 l RNA. For each sample, two treatment groups were
performed, one with reverse transcriptase (RT+ ) and one
without (RT ). The samples were then incubated for 50
minutes at 428C followed by 15 minutes at 708C and ice for 5
minutes. RNase H (2 l ) was added to each tube, and was
then incubated for 20 minutes at 378C.
PCR was then performed using primers designed for the
murine EP1, EP4, and GAPDH nucleotide sequences.
Primer sequences are as follows: EP1 sense (574–602
coding sequence, CTGGGTCCCCCGGGCGGCTGGCGC-
CAGGC), EP1 anti -sense (980–1005, CAGGAACAG-
TGGCCGCTGCAGGGAGG), EP4 sense (49–72, CTGAA-
CAGCCCAGTGACCATCCCG), EP4 antisense (391–411,
GCCCGCCAATCGCTTGTCCAC), mouse GAPDH sense
(43–67, CAAAATGGTGAAGGTCGGTGTGAAC), mouse
GAPDH antisense (294–265, ATGTTAGTGGGGTCTC-
GCTCCTGGAAGATG). PCRs were amplified using 1 l of
cDNA from RT reactions. Each PCR contained 10 mM of the
respective primers (EP1, EP4, or GAPDH), 0.2 mM dNTP, 9
mM or 1.5 mM (EP/GAPDH, respectively) MgCl2, 1PCR
buffer (20 mM Tris–HCl pH 8.4, 50 mM KCl), 0.5 l Taq
polymerase (5 U/l; Gibco, Rockville, MD), and nuclease
free water per 50 l reaction. The PCR amplification cycle
consisted of 958C for 5 minutes initial denaturing step,
followed by 958C for 1 minute, 638C for 1 minute, 728C for 1
minute for 30 cycles, and ending with 728C for 15 minutes.
Twenty microliters of sample was analyzed by electro-
phoresis on a 1.2% agarose gel. The EP1, EP4, and GAPDH
primers should produce PCR product sizes of 431, 362, and
222 base pairs, respectively.
Quantification of EP Receptors
Cells were harvested and fixed in 4% paraformaldehyde.
Cells were washed in PBS and 30 mM SSC. Cells were
incubated in 300 mM glycine, then in permeabilization buffer.
A 1:300 dilution of primary antibody was added, and the cells
were rotated overnight at 48C. Cells were washed in SSC.
FITC-conjugated rabbit anti–chicken secondary antibody
(cat# F-8888; Sigma) diluted 1:250 was added, and cells
were incubated for 1 hour. Cells were washed, and
resuspended in 30 mM SSC. Then, relative fluorescence
units per cell were read on a flow cytometer.
Results
Cell Line 6RI is Invasive
The cell line 6R90 was derived from the benign
papilloma-producing mouse keratinocyte cell line, 308
[48]. An invasive variant of the 6R90 cell line was
subsequently isolated from an invasive tumor formed by
injecting 6R90 cells subcutaneously into athymic nude
mice. To test the stability of the invasive phenotype, the
cell line 6RI was injected subcutaneously into athymic
nude mice. All 12 6RI injection sites developed tumors, and
these tumors appeared in 1 to 2 weeks. All 16 6R90
injection sites developed tumors in 2 to 3 weeks. Tumors
were harvested at 10 weeks and examined by H&E stain to
determine if the tumors had invaded the underlying muscle.
In Figure 1, a photomicrograph is shown of typical margins
for 6R90 and 6RI tumors. The 6R90 tumor had a pushing
margin, whereas all the 6RI tumors had clearly invaded the
underlying muscle.
6R90 and 6RI Cells Have Increased COX Expression
We examined the expression of COX proteins while
looking for possible sources of reactive oxygen species in
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6R90 cells. COX-1 and -2 were examined by Western blot
analysis. The COX enzymes are responsible for converting
AA into PGH2. Western blots for either COX-1 or -2
showed elevated levels in both malignant variants over the
parental 308 cells as seen in Figure 2. The 6RI cells
expressed higher levels of both COX-1 and -2 than the
6R90 cells. The 6R90 cells showed an increase in enzyme
expression over the 308 cells. Thus, there was a trend of
increasing amounts of enzyme expression as the cells
progress from benign to malignant to highly invasive.
Expression of PGE synthase, also called PGH–PGE
isomerase, was also examined by Western blot analyses.
This enzyme is responsible for converting PGH2 into PGE2.
This analysis showed no increase in protein expression in
either malignant cell line compared to the benign 308 cells
(data not shown).
To test whether these enzymes were active, PGE2
was measured in cultured cells. Cells were lysed and
combined cellular and secreted PGE2 was measured by
EIA. The results shown in Figure 3 demonstrate that the
6RI cells have the greatest PGE2 production at 16.45
pg/well per 5000 cells, followed by the 6R90 cells at
12.03 pg/well per 5000 cells. The cell line 308 produced
little, if any, PGE2 with an average of 1.82 pg/well per
5000 cells. As the cells progressed in terms of their
malignant phenotype, the amount of PGE2 produced
increased.
Murine Keratinocyte Cell Lines Express PGE2 Receptors
The cell lines were examined by observing immuno-
fluorescence to determine if they expressed receptors for
PGE2. The staining for these receptors (Figure 4 )
indicated that all three cell lines expressed the EP1 and
EP4 prostanoid receptors. Staining for the EP2 and EP3
prostanoid receptors was negative (data not shown). To
confirm these results, RT-PCR was performed on RNA
isolated from the cell lines. This confirmed that the EP1
and EP4 prostanoid receptors were transcribed in all three
cell lines (data not shown). RT-PCR was not performed
for EP2 or EP3. Because these cells also produce the
ligand for these receptors, there could be autocrine or
paracrine PG regulation of cellular functions, including
growth.
To compare expression levels of these receptors,
flow cytometry was used. In these experiments, a
Figure 2. The malignant cell lines have increased COX expression. This is a
Western blot analysis of COX-1 and -2 in 308, 6R90, and 6RI cells. Forty
micrograms of protein lysate was fractionated by SDS-PAGE. After trans-
ferring the protein to PVDF membrane, the blots were probed with antibody
specific to either COX -1 or - 2 as indicated.
Figure 3. PGE2 production. EIA was performed to measure PGE2 production.
The cells were grown under normal culture conditions in 96 -well plates and
lysed in the plate. A sample was then taken for analysis by EIA. The bars
indicate 95% confidence intervals. The asterisk indicates a significant
difference compared to 308 cells with a P value < .01 by analysis of variance.
Figure 1. The cell line 6RI is invasive. A total of 510 6 cells were injected subcutaneously into athymic nude mice. Tumors were harvested and H&E-stained. A
representative margin is shown. The bars in the upper left corners represent 500 m. (A ) Tumor formed by the cell line 6R90. The arrow shows a regular margin that
does not invade the underlying tissue. (B ) Tumor formed by the cell line 6RI. The arrow shows the tumor invading the underlying muscle.
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FITC-conjugated secondary antibody labeled the recep-
tors, and the average intensity of fluorescence per cell
was recorded. The data shown in Figure 5 indicated
that the 308 and 6R90 cell lines had equivalent
expression of receptors. The 6RI cells demonstrated a
two- fold increase in EP1 and EP4 prostanoid receptor
expression.
Malignant Variants of 308 Cells Depend on PGE2 for Growth
Because the cells produce PGE2 and express recep-
tors for PGE2, we tested the cells for changes in growth
rate after changes in PG production. The cells were
treated with 10 M indomethacin, a nonselective COX
inhibitor, and various amounts of PGE2. The amount of
PGE2 added to the medium was based on the projected
cell count and the amount of PGE2 that would be
produced by that number of cells as predicted by the
PGE2 production measured in Figure 3. This amount
varied between 0.025 and 1.67 nM. The results of these
treatments (Figure 6 ) showed that the growth of the 6R90
and 6RI cells was reduced by 62% and 46%, respectively,
in the presence of indomethacin. This growth inhibition
Figure 4. Immunohistochemical staining for EP receptors. Cells were grown on cover slips under normal culture conditions and stained for the EP receptors. The
counterstain was DAPI staining of the nucleus. (A ) 308 Cells incubated with secondary antibody. (B ) 6R90 Cells incubated with secondary antibody. (C ) 6RI Cells
incubated with secondary antibody. (D ) 308 Cells stained for EP1. (E ) 6R90 Cells stained for EP1. (F ) 6RI Cells stained for EP1. (G ) 308 Cells stained for EP4. (H )
6R90 Cells stained for EP4. ( I ) 6RI Cells stained for EP4.
Figure 5. Quantification of EP receptors. A total of 10 6 cells were stained for
the EP1 and EP4 receptors. Data are expressed as fold of 308 staining. The
bars indicate the standard deviation from five experiments.
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was reversed by the addition of PGE2 to the medium.
This shows that, although production of other eicosanoids
could be inhibited by indomethacin, the growth of these
cells depends on PGE2 production.
A similar experiment was then performed to determine if
the PGE2- induced growth of these cells depends on
activation of a specific receptor. Rescue from indometha-
cin- induced growth inhibition was performed with 17-phenyl
trinor PGE2, an EP1 and EP3 selective agonist with
concentrations as derived for PGE2. Figure 7 shows that
17-phenyl trinor PGE2 can rescue the cells from indome-
thacin- induced growth inhibition. Because the cells do not
express the EP3 prostanoid receptor, the growth signaling is
through the EP1 prostanoid receptor.
Discussion
Our results indicate that the model of skin tumor progression
examined has all of the components necessary to comprise
an autocrine growth-signaling loop. The cells exhibit
increased expression of the enzymes necessary to produce
PGE2 including COX-1 and -2. The activity of these
enzymes was deduced by measurements of PGE2 produc-
tion. The cells also express the EP1 and EP4 prostanoid
receptors for this eicosanoid. Thus, there could be autocrine
Figure 6. A total of 10 4 cells were plated and counted every 12 hours for 48
hours. Cells were treated with vehicle control ( ethanol, EtOH) or 10 M
indomethacin ( indo. ) or 10 M indomethacin and PGE2 ( indo., PGE2 ). The
bars indicate the standard deviation from three experiments. (A ) Growth
curve of 308 cells. (B ) Growth curve of 6R90 cells. (C ) Growth curve of 6RI
cells.
Figure 7. A total of 10 4 cells were plated and counted every 12 hours for 48
hours. Cells were treated with vehicle control ( ethanol, EtOH) or 10 M
indomethacin ( indo. ) or 10 M indomethacin and 17 -phenyl trinor PGE2 (an
EP1 and EP3 agonist ) ( indo., EP1 ag ). The bars indicate the standard
deviation from three experiments. (A ) Growth curve of 308 cells. (B ) Growth
curve of 6R90 cells. (C ) Growth curve of 6RI cells.
Neoplasia . Vol. 3, No. 5, 2001
PGE2 Signaling Contributes to Keratinocyte Growth Thompson et al. 407
or paracrine PG signaling in these cell lines. Additionally,
these cells exhibit an increased growth rate when ligand
binding activates the EP1 prostanoid receptor.
Elevation of COX expression and activity has been
observed in squamous cell carcinomas [19,20]. This is also
a common finding in colon cancer [50]. The fact that
nonsteroidal anti - inflammatory drugs can decrease colon
tumor incidence [4] indicates that some products of these
enzymes influence tumor growth. Recent studies by Fischer
et al. [37] also indicate that inhibition of COX-2 can
decrease the rate of skin tumor promotion. This influence
could be through downstream products of further metabolism
of PGH2, or it could be due to the reactive oxygen species
produced by the activity of the COX enzymes [51]. In the
work reported here, we present evidence that the growth of
the cell lines studied depends on PGE2 production; and that
the PGE2 can engage the EP1 prostanoid receptor to exert
its effects on growth.
PGE2 production can be regulated at several levels. It is
interesting to note that there are reports suggesting that
the various enzymes involved in production of PGE2 are
coregulated. PLA2 activation by phosphorylation has been
shown to occur concurrently with COX-2 production [52].
It has also been shown that dexamethasone can simulta-
neously downregulate COX-2 and PGE synthase [53].
Thus, upregulation of one part of the PGE2 biosynthesis
pathway may occur in the presence of some sort of
upregulation of one or more of the other members of the
pathway. When an increase in COX-2 and PGE synthase
activity occurs, it has been shown to lead to an increased
growth rate [53].
PGE2 in the tumor could come from several sources,
including the tumor cells themselves, cells surrounding the
tumor or infiltrating immune cells. Because PGE2 is unstable,
it is unlikely that PGE2 produced at distant sites would affect
the tumor cells. Squamous cell carcinomas often form at
sites of chronic inflammation [51], thus the production of
PGE2 by immune cells could stimulate growth of cells that
still have normal regulation of COX enzymes. In this context,
PGE2 could act as a tumor promoter by engaging the EP1
receptor on cells that have been initiated. It is of interest that
addition of PGE2 to growth medium can increase the growth
rate of human keratinocytes [42].
Although the EP4 prostanoid receptor does not appear to
play a role in growth regulation of the cells, it could be
involved in other aspects of the malignant phenotype. The
EP4 prostanoid receptor has been shown to localize to the
nuclear membrane [54] where its activation could influence
transcription factors. In rat large granular lymphocytes, a
model of natural killer cells, activation of the EP4 prostanoid
receptor has been shown to be responsible for increased
production of matrix metalloproteinases [55]. PGE2 can also
influence head and neck squamous cell carcinoma migration
and adherence to fibronectin. The authors of this study also
show that this adherence is dependent on protein kinase A
(PKA) activity [44], although they did not demonstrate
specific involvement of either the EP2 or the EP4 receptor.
Although the EP4 prostanoid receptor is not responsible for
the growth of the cells, it could influence transcription factor
activity and possibly invasion.
The EP1 prostanoid receptor is coupled to the Gq - type
G-protein. This protein acts by activation of PLC-. The
products of activation of PLC- are DAG and IP3 [46]. IP3
causes the release of calcium from intracellular stores
[46]. This release of calcium can influence signal trans-
duction at several levels. It has recently been demon-
strated that calcium can activate the Ras pathway through
proline- rich tyrosine kinase 2 [46]. Together with DAG,
calcium can also activate PKC [46]. Both of these
pathways can then activate the mitogen-activated protein
kinase pathways (MAPK) [46]. Many MAPKs have tran-
scription factors as substrates [46], and thus activation of
MAPKs can change the transcription of genes, including
those involved in cell division [46]. Thus, EP1 prostanoid
receptors may modulate cell growth by activation of the
Ras and PKC pathways.
Some of the cellular effects of activating the EP1
prostanoid receptor may be due to the induced expression
of proto-oncogenes. In a recent report, it was shown that
activation of the EP1 prostanoid receptor could induce
expression of the proto-oncogenes, c- jun and c- fos, thus
activating the AP-1 transcription factor [56]. It is reasonable
to think that this induction could lead to activation of genes
controlled by a TPA responsive element. Of interest, Young
et al. [57] recently demonstrated that AP-1 activation is
required for TPA- induced skin tumor promotion. Therefore,
antagonists of the EP1 prostanoid receptor could, in
principle, block activation of the AP-1 transcription factor
complex.
The EP1 prostanoid receptor has recently been impli-
cated in colon carcinogenesis. Using a pharmacologic
antagonist, Watanabe et al. [58] have shown that this
antagonist can inhibit the formation of aberrant crypt foci
after azoxymethane treatment of mice. The antagonist was
given in various amounts in the diet. This resulted in a dose-
dependent inhibition of aberrant crypt foci formation up to
36% of control. Additional evidence of a role for EP1
prostanoid receptors in colon cancer comes from experi-
ments in which Min mice (mice with a nonsense mutation in
the adenomatous polyposis coli gene) were fed a diet that
included an EP1 antagonist. In these studies, the appear-
ance of aberrant crypt foci was decreased by 43% [59]. The
same group used EP1 knockout mice to examine azoxy-
methane- induced aberrant crypt foci. They found that the
EP1 knockout mice demonstrated 40% fewer aberrant crypt
foci than the wild- type controls, in agreement with the
antagonist studies [59]. Because aberrant crypt foci are
putative premalignant lesions, this gives rise to the interest-
ing possibility that signaling through the EP1 prostanoid
receptor is involved in cancer initiation or promotion in the
colon.
There is strong evidence that production of PGs plays a
role in tumor development. This work, and the work of others,
indicates that PGE2 could play an important role in the
growth of squamous cell carcinomas. This work further
demonstrates that the EP1 prostanoid receptor is important
408 PGE2 Signaling Contributes to Keratinocyte Growth Thompson et al.
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for tumor cell growth in the model examined. Thus, the EP1
prostanoid receptor could become an important target for
therapeutic intervention.
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